Neil Keshvani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neil Keshvani has a total of 247 co-authors. Here are the top co-authors by number of shared publications:
- Ambarish Pandey
Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas
29 shared publications - Amgad Mentias
Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation , 9500 Euclid Ave, Cleveland, OH 44195 , USA
7 shared publications - Dharam Jaydeep Kumbhani
Division of Cardiology, University of Texas Southwestern Medical Center, Dallas, TX
7 shared publications - Gregg Fonarow
Ahmanson-UCLA Cardiomyopathy Center, Division of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA 90095, USA
7 shared publications - Matthew W. Segar
Division of Cardiology, Texas Heart Institute , Houston, TX
6 shared publications - Milind Y. Desai
Heart, Vascular and Thoracic Institute, Cleveland Clinic , 9500 Euclid Avenue, Desk J1-5, Cleveland, OH 44195
6 shared publications
Latest Publications
- 19 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Frailty assessment and the risk of major adverse cardiovascular events after elective surgery
Aims: Frailty may increase the risk of major adverse cardiovascular events (MACE) after non-cardiac surgery. We aimed to assess the association between frailty and MACE after non-cardiac surgery and potential improvements in the performance of the Revised Cardiac Risk Index (RCRI) with the addition of frailty status. Methods and results: We conducted a retrospective cohort study of older US adults insured through Medicare undergoing non-cardiac surgery between January 2015 and September 2021. Frailty was assessed with the Hospital Frailty Risk Score, categorized as low (<5), intermediate (5–14), and high (≥15). The primary outcome was 30-day MACE (mortality, myocardial infarction, stroke, or heart failure). Patients with intermediate/high frailty were propensity-matched 1:1 with low-frailty patients with exact match on age, sex, race, surgical procedure, and RCRI. The incremental utility of adding categorical frailty to RCRI was assessed by comparing concordance statistics and receiver operating characteristics. Among 6 399 535 patients (mean age 73 years, 43% male), 22.4% had intermediate/high frailty and 2.97% experienced 30-day MACE. In the propensity-matched cohort, frailty was associated with higher odds of 30-day MACE [OR (95% CI): 1.19 (1.17–1.21), P < 0.001] and mortality [OR (95% CI): 1.53 (1.49–1.58), P < 0.001]. The association of frailty with MACE was stronger in patients with low baseline cardiac risk [RCRI 0–1: OR (95% CI): 1.28 (1.25–1.31)] vs. high risk [RCRI 2–4: OR (95% CI): 1.06 (1.03–1.09); Pinteraction < 0.001]. Adding frailty to RCRI improved predictive performance for 30-day MACE (C-index: 0.773 vs. 0.758, P < 0.001; Brier score: 0.0277 vs. 0.0290). Conclusion: Frailty before non-cardiac surgery was associated with increased 30-day MACE. Incorporating frailty into RCRI improves risk prediction, particularly for patients with low baseline cardiac risk.
- 19 August 2026
- Published by Oxford University Press (OUP) in European Heart Journal: Acute Cardiovascular Care
Frailty assessment and the risk of major adverse cardiovascular events after elective surgery
Aims: Frailty may increase the risk of major adverse cardiovascular events (MACE) after non-cardiac surgery. We aimed to assess the association between frailty and MACE after non-cardiac surgery and potential improvements in the performance of the Revised Cardiac Risk Index (RCRI) with the addition of frailty status. Methods and results: We conducted a retrospective cohort study of older US adults insured through Medicare undergoing non-cardiac surgery between January 2015 and September 2021. Frailty was assessed with the Hospital Frailty Risk Score, categorized as low (<5), intermediate (5–14), and high (≥15). The primary outcome was 30-day MACE (mortality, myocardial infarction, stroke, or heart failure). Patients with intermediate/high frailty were propensity-matched 1:1 with low-frailty patients with exact match on age, sex, race, surgical procedure, and RCRI. The incremental utility of adding categorical frailty to RCRI was assessed by comparing concordance statistics and receiver operating characteristics. Among 6 399 535 patients (mean age 73 years, 43% male), 22.4% had intermediate/high frailty and 2.97% experienced 30-day MACE. In the propensity-matched cohort, frailty was associated with higher odds of 30-day MACE [OR (95% CI): 1.19 (1.17–1.21), P < 0.001] and mortality [OR (95% CI): 1.53 (1.49–1.58), P < 0.001]. The association of frailty with MACE was stronger in patients with low baseline cardiac risk [RCRI 0–1: OR (95% CI): 1.28 (1.25–1.31)] vs. high risk [RCRI 2–4: OR (95% CI): 1.06 (1.03–1.09); Pinteraction < 0.001]. Adding frailty to RCRI improved predictive performance for 30-day MACE (C-index: 0.773 vs. 0.758, P < 0.001; Brier score: 0.0277 vs. 0.0290). Conclusion: Frailty before non-cardiac surgery was associated with increased 30-day MACE. Incorporating frailty into RCRI improves risk prediction, particularly for patients with low baseline cardiac risk.
- 15 July 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (5) , 918-923
A pilot randomized controlled trial protocol of overground robotic exoskeleton–assisted early ambulation after cardiovascular and thoracic surgery in the acute care setting (REACT-CVTS)
Early ambulation following cardiovascular and thoracic surgery (CVTS) is associated with improved postoperative outcomes. However, barriers such as patient debility, high acuity, hemodynamic instability, cardiopulmonary complications, or resource limitations (e.g., intensive care unit setting, specialized equipment, or staff training) often prevent or delay early ambulation. Overground robotic exoskeletons (ORE) may facilitate earlier and higher-dose ambulation, yet their role in acute CVTS recovery remains uninvestigated. To evaluate the safety, feasibility, and preliminary outcomes of ORE-assisted early ambulation in postoperative CVTS patients in the intensive care unit setting, we will conduct a single-center pilot randomized controlled trial. Twenty participants will be randomized 2:1 to receive either ORE plus usual care or usual care alone. Primary outcomes include time from intensive care unit admission to first upright ambulation (hours) and ambulation dosage (upright time, walking time, and steps). Secondary outcomes assess safety (adverse events) and feasibility (staffing requirements). This randomized controlled trial is the first investigation of ORE for early ambulation in the CVTS population and will lay the groundwork for the integration of advanced ORE technology into cardiopulmonary rehabilitation.
- 15 July 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (5) , 918-923
A pilot randomized controlled trial protocol of overground robotic exoskeleton–assisted early ambulation after cardiovascular and thoracic surgery in the acute care setting (REACT-CVTS)
Early ambulation following cardiovascular and thoracic surgery (CVTS) is associated with improved postoperative outcomes. However, barriers such as patient debility, high acuity, hemodynamic instability, cardiopulmonary complications, or resource limitations (e.g., intensive care unit setting, specialized equipment, or staff training) often prevent or delay early ambulation. Overground robotic exoskeletons (ORE) may facilitate earlier and higher-dose ambulation, yet their role in acute CVTS recovery remains uninvestigated. To evaluate the safety, feasibility, and preliminary outcomes of ORE-assisted early ambulation in postoperative CVTS patients in the intensive care unit setting, we will conduct a single-center pilot randomized controlled trial. Twenty participants will be randomized 2:1 to receive either ORE plus usual care or usual care alone. Primary outcomes include time from intensive care unit admission to first upright ambulation (hours) and ambulation dosage (upright time, walking time, and steps). Secondary outcomes assess safety (adverse events) and feasibility (staffing requirements). This randomized controlled trial is the first investigation of ORE for early ambulation in the CVTS population and will lay the groundwork for the integration of advanced ORE technology into cardiopulmonary rehabilitation.
- 29 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (38) , 5593-5596
Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity
- 29 June 2026
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 47 (38) , 5593-5596
Weight loss, exercise haemodynamics, and health status with incretin therapy for heart failure with preserved ejection fraction and obesity
- 25 June 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Diuretic resistance risk and the efficacy of torsemide vs furosemide: a post-hoc analysis of the TRANSFORM-HF trial
Background/Aims: Among hospitalized patients with heart failure (HF), diuretic resistance is associated with residual congestion, poor health status, and increased risk of HF hospitalization and mortality in the post-discharge period. The TRANSFORM-HF trial demonstrated no significant difference between torsemide and furosemide on clinical outcomes or quality-of-life following HF hospitalization. We assessed the association between diuretic resistance risk, assessed using the BAN-ADHF score, with risk of adverse outcomes among participants of the TRANSFORM-HF trial, and whether diuretic resistance risk modified the treatment effects of torsemide vs furosemide. Methods: This post-hoc analysis of TRANSFORM-HF included participants randomized to torsemide or furosemide who survived to discharge with available BAN-ADHF scores. High diuretic resistance risk was defined as BAN-ADHF score ≥12 during index hospitalization. Associations of diuretic resistance risk with 12-month all-cause mortality, all-cause hospitalization, and quality of life (KCCQ-CSS) were assessed using adjusted Cox models, and linear mixed-effects models, respectively. Treatment effect modification was assessed via interaction terms between randomized treatment and diuretic resistance risk status (high vs low). Results: Among 2421 participants (age: 65 years, 62.9% male), 512 (21%) had high diuretic resistance risk. High diuretic resistance risk was independently associated with increased risk of all-cause mortality (aHR[95%CI]: 1.79[1.45–2.21], P < .001), all-cause hospitalization (aHR: 1.34[1.15–1.55], P < .001), and lower 12-month KCCQ-CSS improvement (−3.4 points, P = .037). Diuretic resistance risk status did not modify the treatment effect of torsemide vs furosemide on all-cause mortality (Pinteraction = .54), all-cause hospitalization (Pinteraction = .74), or quality-of-life on follow-up (Pinteraction > .05 at each timepoint). Conclusion: Among patients discharged after HF hospitalization, higher diuretic resistance risk, assessed by the BAN-ADHF score, is associated with higher risk of mortality, HF hospitalization, and worse quality-of-life. Diuretic resistance risk status did not modify the treatment effects of torsemide vs furosemide.
- 25 June 2026
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
Diuretic resistance risk and the efficacy of torsemide vs furosemide: a post-hoc analysis of the TRANSFORM-HF trial
Background/Aims: Among hospitalized patients with heart failure (HF), diuretic resistance is associated with residual congestion, poor health status, and increased risk of HF hospitalization and mortality in the post-discharge period. The TRANSFORM-HF trial demonstrated no significant difference between torsemide and furosemide on clinical outcomes or quality-of-life following HF hospitalization. We assessed the association between diuretic resistance risk, assessed using the BAN-ADHF score, with risk of adverse outcomes among participants of the TRANSFORM-HF trial, and whether diuretic resistance risk modified the treatment effects of torsemide vs furosemide. Methods: This post-hoc analysis of TRANSFORM-HF included participants randomized to torsemide or furosemide who survived to discharge with available BAN-ADHF scores. High diuretic resistance risk was defined as BAN-ADHF score ≥12 during index hospitalization. Associations of diuretic resistance risk with 12-month all-cause mortality, all-cause hospitalization, and quality of life (KCCQ-CSS) were assessed using adjusted Cox models, and linear mixed-effects models, respectively. Treatment effect modification was assessed via interaction terms between randomized treatment and diuretic resistance risk status (high vs low). Results: Among 2421 participants (age: 65 years, 62.9% male), 512 (21%) had high diuretic resistance risk. High diuretic resistance risk was independently associated with increased risk of all-cause mortality (aHR[95%CI]: 1.79[1.45–2.21], P < .001), all-cause hospitalization (aHR: 1.34[1.15–1.55], P < .001), and lower 12-month KCCQ-CSS improvement (−3.4 points, P = .037). Diuretic resistance risk status did not modify the treatment effect of torsemide vs furosemide on all-cause mortality (Pinteraction = .54), all-cause hospitalization (Pinteraction = .74), or quality-of-life on follow-up (Pinteraction > .05 at each timepoint). Conclusion: Among patients discharged after HF hospitalization, higher diuretic resistance risk, assessed by the BAN-ADHF score, is associated with higher risk of mortality, HF hospitalization, and worse quality-of-life. Diuretic resistance risk status did not modify the treatment effects of torsemide vs furosemide.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 19 (2)
Patient Perspectives on a Polypill Strategy for Heart Failure With Reduced Ejection Fraction: A Convergent-Parallel Mixed Methods Study Embedded in a Randomized Clinical Trial
BACKGROUND: Heart failure with reduced ejection fraction guideline-directed medical therapy remains underused, particularly in socioeconomically disadvantaged populations. It has been proposed that the use of combination pills (polypills) may facilitate prescribing of guideline-directed medical therapy and increase adherence. Understanding patient perspectives on implementation barriers and facilitators to the use of polypills is needed for developing effective strategies. METHODS: A convergent, parallel, mixed-methods study was conducted with participants who participated in a phase II randomized controlled trial of a heart failure with reduced ejection fraction polypill (POLY HF) in Dallas, TX. Six focus groups were conducted with participants from both polypill and usual care arms, followed by brief surveys. Qualitative data were analyzed using directed content analysis organized by a socioecological framework to identify barriers and facilitators across individual, interpersonal, and systems levels. Descriptive statistics characterized medication burden and polypill preferences. RESULTS: Study participants (n=41) included trial participants (n=36, mean 53 years, 53% Black race, 39% Hispanic) and caregivers (n=5). Quantitative data revealed substantial medication burden, with 58% taking ≥6 medications and 50.0% reporting missed doses, primarily due to forgetting (44%). 88.6% expressed interest in a polypill approach, and 83% believed it would improve adherence. Qualitative analysis identified multilevel implementation barriers and facilitators. Individual-level barriers included pill size concerns and uncertainty about polypill contents, while facilitators encompassed reduced pill burden, psychological benefits of taking fewer medications, and perceived health improvements. Interpersonal facilitators included caregiver enthusiasm for simplified medication management and strong provider trust. Systems-level barriers centered on cost concerns, while institutional trust facilitated acceptance. Mixed-methods integration revealed convergent findings. Quantitative medication burden aligned with qualitative themes of regimen complexity, while high quantitative interest in polypills was contextualized by practical implementation considerations regarding formulation and delivery. CONCLUSIONS: In socioeconomically disadvantaged patients with heart failure with reduced ejection fraction, a polypill strategy demonstrated strong patient acceptability, supporting further implementation research. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04633005.
- 1 February 2026
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 19 (2)
Patient Perspectives on a Polypill Strategy for Heart Failure With Reduced Ejection Fraction: A Convergent-Parallel Mixed Methods Study Embedded in a Randomized Clinical Trial
BACKGROUND: Heart failure with reduced ejection fraction guideline-directed medical therapy remains underused, particularly in socioeconomically disadvantaged populations. It has been proposed that the use of combination pills (polypills) may facilitate prescribing of guideline-directed medical therapy and increase adherence. Understanding patient perspectives on implementation barriers and facilitators to the use of polypills is needed for developing effective strategies. METHODS: A convergent, parallel, mixed-methods study was conducted with participants who participated in a phase II randomized controlled trial of a heart failure with reduced ejection fraction polypill (POLY HF) in Dallas, TX. Six focus groups were conducted with participants from both polypill and usual care arms, followed by brief surveys. Qualitative data were analyzed using directed content analysis organized by a socioecological framework to identify barriers and facilitators across individual, interpersonal, and systems levels. Descriptive statistics characterized medication burden and polypill preferences. RESULTS: Study participants (n=41) included trial participants (n=36, mean 53 years, 53% Black race, 39% Hispanic) and caregivers (n=5). Quantitative data revealed substantial medication burden, with 58% taking ≥6 medications and 50.0% reporting missed doses, primarily due to forgetting (44%). 88.6% expressed interest in a polypill approach, and 83% believed it would improve adherence. Qualitative analysis identified multilevel implementation barriers and facilitators. Individual-level barriers included pill size concerns and uncertainty about polypill contents, while facilitators encompassed reduced pill burden, psychological benefits of taking fewer medications, and perceived health improvements. Interpersonal facilitators included caregiver enthusiasm for simplified medication management and strong provider trust. Systems-level barriers centered on cost concerns, while institutional trust facilitated acceptance. Mixed-methods integration revealed convergent findings. Quantitative medication burden aligned with qualitative themes of regimen complexity, while high quantitative interest in polypills was contextualized by practical implementation considerations regarding formulation and delivery. CONCLUSIONS: In socioeconomically disadvantaged patients with heart failure with reduced ejection fraction, a polypill strategy demonstrated strong patient acceptability, supporting further implementation research. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04633005.
- 20 January 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (7) , 1186-1195
Association between single-pill combination therapy use and blood pressure control in the Systolic Blood Pressure Reduction Intervention Trial: a post hoc analysis
Aims: Blood pressure (BP) control remains suboptimal among US patients with hypertension. Single-pill combination (SPC) therapies are commonly used to improve adherence; however, their effectiveness for achieving early and sustained intensive BP control is unclear. Methods and results: We performed a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT) including 2736 participants propensity matched in a 1:2 ratio to compare effects of SPCs with equivalent multi-pill therapy. The estimated marginal odds of achieving target BP control were derived using generalized linear mixed models with repeated measures (LMMRMs). The association between time-updated SPC use and BP change in short- (≤6 months) and long-term (>6 months) follow-up was assessed with LMMRM and SPC * time interaction term. Multivariable Cox models evaluated the association of SPC use with cardiovascular events and serious adverse events (SAEs). Among SPRINT participants (n = 8623), 9.3% (n = 803) were prescribed SPC at baseline with greater use in the intensive vs. usual care group (5.79 vs. 3.90 per 100 person-months; P-diff < 0.001). Among matched pairs [SPC (n = 912); multi-pill therapy (n = 1824)], SPC use was associated with 22% increased likelihood of achieving target BP by 6 months [odds ratio (95% confidence interval), 1.22 (1.05, 1.42)]. Participants receiving SPCs (vs. multi-pills) experienced more rapid BP reduction in the first 6 months (−2.0 vs. −1.2 mmHg monthly change; P-diff < 0.001). Over long-term follow-up, participants using SPCs achieved significantly lower SBP at each time point. The risk of the primary CV composite endpoint and SAEs were not significantly different between groups. Conclusion: Single-pill combination use resulted in greater likelihood of achieving target BP control and more rapid, sustained BP reduction without an increase in SAEs.
- 20 January 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (7) , 1186-1195
Association between single-pill combination therapy use and blood pressure control in the Systolic Blood Pressure Reduction Intervention Trial: a post hoc analysis
Aims: Blood pressure (BP) control remains suboptimal among US patients with hypertension. Single-pill combination (SPC) therapies are commonly used to improve adherence; however, their effectiveness for achieving early and sustained intensive BP control is unclear. Methods and results: We performed a post hoc analysis of Systolic Blood Pressure Intervention Trial (SPRINT) including 2736 participants propensity matched in a 1:2 ratio to compare effects of SPCs with equivalent multi-pill therapy. The estimated marginal odds of achieving target BP control were derived using generalized linear mixed models with repeated measures (LMMRMs). The association between time-updated SPC use and BP change in short- (≤6 months) and long-term (>6 months) follow-up was assessed with LMMRM and SPC * time interaction term. Multivariable Cox models evaluated the association of SPC use with cardiovascular events and serious adverse events (SAEs). Among SPRINT participants (n = 8623), 9.3% (n = 803) were prescribed SPC at baseline with greater use in the intensive vs. usual care group (5.79 vs. 3.90 per 100 person-months; P-diff < 0.001). Among matched pairs [SPC (n = 912); multi-pill therapy (n = 1824)], SPC use was associated with 22% increased likelihood of achieving target BP by 6 months [odds ratio (95% confidence interval), 1.22 (1.05, 1.42)]. Participants receiving SPCs (vs. multi-pills) experienced more rapid BP reduction in the first 6 months (−2.0 vs. −1.2 mmHg monthly change; P-diff < 0.001). Over long-term follow-up, participants using SPCs achieved significantly lower SBP at each time point. The risk of the primary CV composite endpoint and SAEs were not significantly different between groups. Conclusion: Single-pill combination use resulted in greater likelihood of achieving target BP control and more rapid, sustained BP reduction without an increase in SAEs.
- Open Access
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e037165
Procedural Volume and Outcomes in Lower‐Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry
Background: Lower‐extremity peripheral vascular interventions (PVIs) are increasingly used for treatment of peripheral artery disease. However, the relationship between hospital and operator PVI volume with in‐hospital major adverse limb events (MALEs) and major adverse cardiovascular events (MACEs) is not well established. Methods: We used the NCDR PVI (National Cardiovascular Data Registry) registry, including procedural data from April 1, 2014, to December 31, 2019, assessing in‐hospital MALEs and MACEs during hospitalization for PVI. Annualized PVI volumes were categorized on the basis of operator or site volume. Generalized linear mixed models assessed volume–outcome relationships after adjustment of covariates. Results: Between 2014 and 2019, 55 785 PVI procedures were performed at 97 hospitals by 555 operators. Adjusted analysis showed no statistically significant association between hospital volume and MALEs (highest versus lowest volume: odds ratio, 0.91 [95% CI, 0.74–1.11]; P =0.35) or hospital volume and MACEs (highest versus lowest volume: odds ratio, 1.23 [95% CI, 0.95–1.16]; P= 0.12). Notably, undergoing PVI with high‐volume operators was associated with lower odds of in‐hospital MALEs (odds ratio, 0.73 [95% CI, 0.55–0.97]; P= 0.03) and MACEs (odds ratio, 0.64 [95% CI, 0.44–0.95]; P= 0.03). Female sex and comorbidities including dyslipidemia, prior percutaneous coronary intervention, heart failure, and acute or chronic limb ischemia were associated with higher MALE risk. Older age and comorbidities including hypertension, dyslipidemia, end‐stage renal disease requiring dialysis, severe lung disease, prior myocardial infarction, heart failure, and acute limb ischemia were associated with greater MACE risk. Conclusions: In contemporary practice, a significant relationship was observed between operator volume and adjusted PVI outcomes. Highest‐volume operators had lower rates of in‐hospital MALEs and MACEs compared with lowest‐volume operators.
- 4 November 2025
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 14 (21) , e037165
Open AccessProcedural Volume and Outcomes in Lower‐Extremity Peripheral Vascular Interventions: Insights From the NCDR Peripheral Vascular Intervention Registry
Background: Lower‐extremity peripheral vascular interventions (PVIs) are increasingly used for treatment of peripheral artery disease. However, the relationship between hospital and operator PVI volume with in‐hospital major adverse limb events (MALEs) and major adverse cardiovascular events (MACEs) is not well established. Methods: We used the NCDR PVI (National Cardiovascular Data Registry) registry, including procedural data from April 1, 2014, to December 31, 2019, assessing in‐hospital MALEs and MACEs during hospitalization for PVI. Annualized PVI volumes were categorized on the basis of operator or site volume. Generalized linear mixed models assessed volume–outcome relationships after adjustment of covariates. Results: Between 2014 and 2019, 55 785 PVI procedures were performed at 97 hospitals by 555 operators. Adjusted analysis showed no statistically significant association between hospital volume and MALEs (highest versus lowest volume: odds ratio, 0.91 [95% CI, 0.74–1.11]; P =0.35) or hospital volume and MACEs (highest versus lowest volume: odds ratio, 1.23 [95% CI, 0.95–1.16]; P= 0.12). Notably, undergoing PVI with high‐volume operators was associated with lower odds of in‐hospital MALEs (odds ratio, 0.73 [95% CI, 0.55–0.97]; P= 0.03) and MACEs (odds ratio, 0.64 [95% CI, 0.44–0.95]; P= 0.03). Female sex and comorbidities including dyslipidemia, prior percutaneous coronary intervention, heart failure, and acute or chronic limb ischemia were associated with higher MALE risk. Older age and comorbidities including hypertension, dyslipidemia, end‐stage renal disease requiring dialysis, severe lung disease, prior myocardial infarction, heart failure, and acute limb ischemia were associated with greater MACE risk. Conclusions: In contemporary practice, a significant relationship was observed between operator volume and adjusted PVI outcomes. Highest‐volume operators had lower rates of in‐hospital MALEs and MACEs compared with lowest‐volume operators.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (10) , e012136
Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare Beneficiaries
BACKGROUND: Type 2 myocardial infarction (MI) is common among older adults and is associated with adverse outcomes in single-center studies. We aimed to examine temporal trends and compare outcomes between type 1 and type 2 MI in Medicare beneficiaries. METHODS: Medicare beneficiaries with type 1 or type 2 MI were identified using International Classification of Diseases, Tenth Revision codes from Medicare Provider Analysis and Review 100% inpatient files. Temporal trends were assessed from 2018 to 2021. Patients with type 2 MI were matched 1:1 to type 1 MI by age, sex, race, and year. Outcomes included all-cause mortality, recurrent MI, heart failure hospitalization (HFH), and stroke. Time-to-event analyses used Cox models for mortality and Fine-Gray models for hospitalization outcomes, with short-term (≤30 days) and long-term (>30 days) outcomes assessed using landmark analysis. RESULTS: Among 1 816 926 Medicare beneficiaries, the proportion of type 2 MI increased from 19.4% in 2018 to 26.8% in 2021 ( P trend <0.001). In propensity-matched analyses of 94 132 patients (mean age 77.3±11 years, 53.3% male), patients with type 2 (versus type 1) MI had lower short-term all-cause mortality (hazard ratio, 0.61 [95% CI, 0.59–0.63]), recurrent MI (subdistribution hazard ratio [sHR], 0.56 [95% CI, 0.54–0.59]), HFH (sHR, 0.56 [95% CI, 0.47–0.67]), and similar risk of stroke (sHR, 1.04 [95% CI, 0.90–1.21]). In long-term, patients with type 2 (versus type 1) MI had higher risk of all-cause mortality (hazard ratio, 1.23 [95% CI, 1.20–1.26]) and stroke (sHR, 1.20 [95% CI, 1.10–1.31]). The risk of recurrent MI and HFH associated with type 2 (versus type 1) MI in long-term follow-up was lower but considerably attenuated in magnitude compared with short-term risk (recurrent MI: sHR, 0.89 [95% CI, 0.86–0.94]; HFH; sHR, 0.73 [95% CI, 0.66–0.81]). CONCLUSIONS: Type 2 MI now accounts for over one-quarter of all MIs and is increasingly diagnosed. While patients with type 1 MI had higher short-term all-cause mortality risk, those with type 2 MI demonstrated higher long-term all-cause mortality and stroke risk, with lower risk of recurrent MI and HFH. These results highlight an urgent need for evidence-based strategies in this high-risk population.
- 1 October 2025
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 18 (10) , e012136
Temporal Trends, Patient Characteristics, and Outcomes of Type 2 Versus Type 1 Myocardial Infarction Among Medicare Beneficiaries
BACKGROUND: Type 2 myocardial infarction (MI) is common among older adults and is associated with adverse outcomes in single-center studies. We aimed to examine temporal trends and compare outcomes between type 1 and type 2 MI in Medicare beneficiaries. METHODS: Medicare beneficiaries with type 1 or type 2 MI were identified using International Classification of Diseases, Tenth Revision codes from Medicare Provider Analysis and Review 100% inpatient files. Temporal trends were assessed from 2018 to 2021. Patients with type 2 MI were matched 1:1 to type 1 MI by age, sex, race, and year. Outcomes included all-cause mortality, recurrent MI, heart failure hospitalization (HFH), and stroke. Time-to-event analyses used Cox models for mortality and Fine-Gray models for hospitalization outcomes, with short-term (≤30 days) and long-term (>30 days) outcomes assessed using landmark analysis. RESULTS: Among 1 816 926 Medicare beneficiaries, the proportion of type 2 MI increased from 19.4% in 2018 to 26.8% in 2021 ( P trend <0.001). In propensity-matched analyses of 94 132 patients (mean age 77.3±11 years, 53.3% male), patients with type 2 (versus type 1) MI had lower short-term all-cause mortality (hazard ratio, 0.61 [95% CI, 0.59–0.63]), recurrent MI (subdistribution hazard ratio [sHR], 0.56 [95% CI, 0.54–0.59]), HFH (sHR, 0.56 [95% CI, 0.47–0.67]), and similar risk of stroke (sHR, 1.04 [95% CI, 0.90–1.21]). In long-term, patients with type 2 (versus type 1) MI had higher risk of all-cause mortality (hazard ratio, 1.23 [95% CI, 1.20–1.26]) and stroke (sHR, 1.20 [95% CI, 1.10–1.31]). The risk of recurrent MI and HFH associated with type 2 (versus type 1) MI in long-term follow-up was lower but considerably attenuated in magnitude compared with short-term risk (recurrent MI: sHR, 0.89 [95% CI, 0.86–0.94]; HFH; sHR, 0.73 [95% CI, 0.66–0.81]). CONCLUSIONS: Type 2 MI now accounts for over one-quarter of all MIs and is increasingly diagnosed. While patients with type 1 MI had higher short-term all-cause mortality risk, those with type 2 MI demonstrated higher long-term all-cause mortality and stroke risk, with lower risk of recurrent MI and HFH. These results highlight an urgent need for evidence-based strategies in this high-risk population.
- 14 May 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (8) , 2376-2385
Frailty Burden and Efficacy of Initial Invasive Strategy in Chronic Coronary Disease: The ISCHEMIA Trials
Background: Frailty is common among patients with chronic coronary disease and is associated with worse outcomes. Methods: A pooled, post hoc analysis of the ISCHEMIA and ISCHEMIA‐CKD trials was conducted. Baseline frailty was assessed using a Frailty Index (FI), and participants were categorized into data‐derived tertiles. Multivariable Cox models with multiplicative interaction terms (frailty × treatment arm) were constructed to evaluate whether baseline frailty status modified the treatment effect of the initial invasive (vs conservative) strategy on a composite outcome of cardiovascular death, myocardial infarction, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest and the secondary outcome of HRQoL (Seattle Angina Questionnaire [SAQ]). Results: Among 5322 participants (mean 64 years, 24% female), a high frailty burden (tertile 3 vs. tertile 1) was associated with lower baseline SAQ scores and increased risk of adverse clinical outcomes on follow‐up. Baseline frailty burden did not significantly modify the effect of the initial invasive strategy on the primary composite outcome ( P interaction frailty × intervention arm = 0.30). However, frailty significantly modified the effect of the initial invasive strategy on HRQoL, with higher baseline frailty burden associated with greater improvement in SAQ scores at 1 year with initial invasive (vs. conservative) treatment ( P interaction frailty × intervention arm < 0.001). The treatment effect of an initial invasive vs. conservative strategy on 12‐month SAQ score change was most pronounced in individuals with lower baseline SAQ scores in both higher and lower frailty burden groups. Conclusion: Patients with chronic coronary disease with a higher frailty burden are more likely to experience greater improvements in HRQoL with initial invasive management without a higher risk of adverse clinical events. Lower baseline SAQ scores predicted greater improvement in HRQoL with initial invasive management, independent of frailty burden.
- 14 May 2025
- Published by Wiley in Journal of the American Geriatrics Society
- Vol. 73 (8) , 2376-2385
Frailty Burden and Efficacy of Initial Invasive Strategy in Chronic Coronary Disease: The ISCHEMIA Trials
Background: Frailty is common among patients with chronic coronary disease and is associated with worse outcomes. Methods: A pooled, post hoc analysis of the ISCHEMIA and ISCHEMIA‐CKD trials was conducted. Baseline frailty was assessed using a Frailty Index (FI), and participants were categorized into data‐derived tertiles. Multivariable Cox models with multiplicative interaction terms (frailty × treatment arm) were constructed to evaluate whether baseline frailty status modified the treatment effect of the initial invasive (vs conservative) strategy on a composite outcome of cardiovascular death, myocardial infarction, hospitalization for unstable angina, heart failure, or resuscitated cardiac arrest and the secondary outcome of HRQoL (Seattle Angina Questionnaire [SAQ]). Results: Among 5322 participants (mean 64 years, 24% female), a high frailty burden (tertile 3 vs. tertile 1) was associated with lower baseline SAQ scores and increased risk of adverse clinical outcomes on follow‐up. Baseline frailty burden did not significantly modify the effect of the initial invasive strategy on the primary composite outcome ( P interaction frailty × intervention arm = 0.30). However, frailty significantly modified the effect of the initial invasive strategy on HRQoL, with higher baseline frailty burden associated with greater improvement in SAQ scores at 1 year with initial invasive (vs. conservative) treatment ( P interaction frailty × intervention arm < 0.001). The treatment effect of an initial invasive vs. conservative strategy on 12‐month SAQ score change was most pronounced in individuals with lower baseline SAQ scores in both higher and lower frailty burden groups. Conclusion: Patients with chronic coronary disease with a higher frailty burden are more likely to experience greater improvements in HRQoL with initial invasive management without a higher risk of adverse clinical events. Lower baseline SAQ scores predicted greater improvement in HRQoL with initial invasive management, independent of frailty burden.